Healthcare is experiencing unprecedented advances in life sciences and cutting-edge technologies, accelerated even further by the COVID-19 pandemic. To fully leverage the potential of innovation, as well as knowledge and data, a new approach to citizen-oriented health is needed. We must finally make the shift to personalised prevention, focussing on behavioural change and consumer empowerment, strengthening digital infrastructure, investing in the healthcare workforce, fostering data exchange and international cooperation. This is not just a healthcare revolution but a cultural one.
This session will take you on the journey through the cultural transformation in healthcare driven by technological innovation and scientific advances. You will understand how COVID has catalysed digital and hybrid approaches, which are likely to shape the way organisations deliver and citizens manage their own healthcare in the future.
Session Lead: Claudia Pagliari, Director of Global eHealth, University of Edinburgh.
The COVID-19 pandemic demonstrated that agile health policies, and trust in health authorities from civil society, are necessary for the wealth and health of individuals. In 2022, we will see the impact of proactive health governance implemented during the early waves of the pandemic, but also what is still to come. While early outcomes of recovery and resilience plans give some guidance for decision-makers, initiatives such as EU4Health, a new mandate for EMA and ECDC, HERA, EHDS, EU pharmaceutical strategy and implementation of MDR are changing health ecosystems in EU Member States and across Europe. Is it enough to help us learn and recover from crisis, be prepared for the next and transform challenges into opportunities?
Join us to discuss the components of sustainable health policy and best practices that have proven their value in recent years and gain insight into where policy will go next within the always evolving ‘new normal’.
Session Lead: Andrzej Ryś, Director responsible for Health Systems, medical products and innovation, Directorate-General for Health and Food Safety (DG SANTE), European Commission.
9 top start-ups of the EIT Health Catapult Programme will pitch their innovations live to a panel of judges and the audience. The three podium finalists in each category (medtech, biotech and digital health) will compete for three prizes. One of the finalists will also win the “Alex Casta Audience Award”. This gives them a unique opportunity to have their logo displayed on the Nasdaq Tower in New York’s Times Square, where it will be seen by millions of people worldwide.
Meet the finalists: 21 start-ups reach EIT Health Catapult Final - EIT Health
Onena Medicines (Spain): makes antibody medicines that force drug resistant cancer stem cells to permanently grow old, rendering them incapable of sustaining and spreading cancer.
SideROS (France): a preclinical stage biotech, developing small molecules targeting iron metabolism to fight cancer resistance, responsible for relapse and metastasis.
SolasCure (UK): makes Aurase®, a hydrogel containing a safe, active, highly specific enzyme, isolated and cloned from medical maggots which promotes faster wound cleaning.
Leuko (Spain): develops PointCheck™, a device that can monitor white blood cells non-invasively. White blood cell monitoring is a first-line indicator in cancer chemotherapy and infection detection.
Luminate Medical (Ireland): develops a novel technology to manage off-target drug delivery. Their product, Lily, provides a portable, patient-focused treatment to prevent chemo induced hair loss.
Thinksono (Germany): created the world’s first software for automatic detection of deep vein thrombosis (DVT). DVT is the number one cause of preventable hospital death.
Digital Health category:
AZmed (France): develops AI-powered solutions improving radiologist’s productivity and diagnostics quality. Their first product Rayvolve detects all types of fractures on X-rays.
Brightlobe (UK): has invented patent-pending technology that can assess and support a child’s brain development using clinically validated mobile games.
Ebenbuild (Germany): develops simulation/AI software to generate data about patients’ lungs, enabling doctors to provide better personalised therapy for Acute Respiratory Distress Syndrome (ARDS).